Aptevo Free Cash Flow Yield vs Cash Conversion Cycle Analysis
APVO Stock | USD 9.20 0.47 5.38% |
Aptevo Therapeutics financial indicator trend analysis is way more than just evaluating Aptevo Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Aptevo Therapeutics is a good investment. Please check the relationship between Aptevo Therapeutics Free Cash Flow Yield and its Cash Conversion Cycle accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptevo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Aptevo Stock, please use our How to Invest in Aptevo Therapeutics guide.
Free Cash Flow Yield vs Cash Conversion Cycle
Free Cash Flow Yield vs Cash Conversion Cycle Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Aptevo Therapeutics Free Cash Flow Yield account and Cash Conversion Cycle. At this time, the significance of the direction appears to have strong relationship.
The correlation between Aptevo Therapeutics' Free Cash Flow Yield and Cash Conversion Cycle is 0.79. Overlapping area represents the amount of variation of Free Cash Flow Yield that can explain the historical movement of Cash Conversion Cycle in the same time period over historical financial statements of Aptevo Therapeutics, assuming nothing else is changed. The correlation between historical values of Aptevo Therapeutics' Free Cash Flow Yield and Cash Conversion Cycle is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow Yield of Aptevo Therapeutics are associated (or correlated) with its Cash Conversion Cycle. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash Conversion Cycle has no effect on the direction of Free Cash Flow Yield i.e., Aptevo Therapeutics' Free Cash Flow Yield and Cash Conversion Cycle go up and down completely randomly.
Correlation Coefficient | 0.79 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Free Cash Flow Yield
A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.Cash Conversion Cycle
Most indicators from Aptevo Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Aptevo Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptevo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Aptevo Stock, please use our How to Invest in Aptevo Therapeutics guide.At this time, Aptevo Therapeutics' Selling General Administrative is very stable compared to the past year. As of the 11th of December 2024, Sales General And Administrative To Revenue is likely to grow to 4.21, while Discontinued Operations is likely to drop about 866.1 K.
2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 33.7M | 31.8M | 28.9M | 41.8M | Cost Of Revenue | 19.0M | 901K | 567K | 538.7K |
Aptevo Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Aptevo Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Aptevo Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Common Stock Shares Outstanding | 66.3K | 77.1K | 106.5K | 116.0K | 278.1K | 292.0K | |
Total Assets | 53.4M | 53.5M | 56.6M | 34.2M | 24.8M | 23.6M | |
Other Current Liab | 9.1M | 4.0M | 19.6M | 3.2M | 3.2M | 3.1M | |
Total Current Liabilities | 38.2M | 14.5M | 34.8M | 8.7M | 7.2M | 6.9M | |
Total Stockholder Equity | 11.8M | 16.6M | 1.2M | 18.0M | 12.2M | 11.6M | |
Net Tangible Assets | 7.4M | 16.6M | 1.2M | 18.0M | 16.2M | 18.4M | |
Property Plant And Equipment Net | 7.7M | 5.5M | 4.0M | 6.8M | 5.8M | 5.9M | |
Net Debt | 10.7M | (12.6M) | (28.3M) | (13.1M) | (11.5M) | (10.9M) | |
Retained Earnings | (167.9M) | (185.6M) | (214.1M) | (206.0M) | (223.4M) | (234.6M) | |
Accounts Payable | 13.0M | 5.6M | 3.5M | 3.5M | 4.0M | 6.5M | |
Cash | 12.4M | 40.0M | 45.0M | 22.6M | 16.9M | 21.2M | |
Non Current Assets Total | 23.4M | 6.3M | 4.0M | 6.8M | 5.8M | 5.5M | |
Cash And Short Term Investments | 12.4M | 40.0M | 45.0M | 22.6M | 16.9M | 16.1M | |
Net Receivables | 7.0M | 2.4M | 3.7M | 2.5M | 2.3M | 4.5M | |
Liabilities And Stockholders Equity | 53.4M | 53.5M | 56.6M | 34.2M | 24.8M | 23.6M | |
Non Current Liabilities Total | 3.3M | 22.4M | 20.6M | 7.5M | 5.4M | 5.1M | |
Inventory | 6.1M | 4.8M | 3.1M | 1.6M | 1.4M | 1.3M | |
Other Current Assets | 160K | 4.9M | 3.9M | 2.3M | 2.2M | 3.0M | |
Other Stockholder Equity | 179.7M | 202.2M | 215.2M | 224.0M | 235.6M | 166.4M | |
Total Liab | 41.6M | 37.0M | 55.4M | 16.2M | 12.6M | 12.0M | |
Property Plant And Equipment Gross | 7.7M | 2.8M | 4.0M | 19.8M | 19.4M | 20.3M | |
Total Current Assets | 30.0M | 47.3M | 52.6M | 27.5M | 19.1M | 37.5M | |
Common Stock | 45K | 46K | 47K | 48K | 61K | 58.0K | |
Property Plant Equipment | 7.7M | 5.5M | 4.0M | 6.8M | 7.8M | 5.9M | |
Non Currrent Assets Other | 11.3M | 746K | 68K | (6.8M) | (6.1M) | (5.8M) | |
Other Assets | 8.4M | 11.3M | 3.5M | 68K | 61.2K | 58.1K | |
Short Long Term Debt Total | 23.2M | 27.4M | 16.7M | 9.5M | 5.4M | 5.1M | |
Common Stock Total Equity | 22K | 23K | 45K | 46K | 52.9K | 34.3K | |
Non Current Liabilities Other | 734K | 200K | 3.3M | 15.6M | 17.9M | 18.8M | |
Net Invested Capital | 31.7M | 41.6M | 16.6M | 21.4M | 12.2M | 11.6M |
Pair Trading with Aptevo Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aptevo Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aptevo Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Aptevo Stock
0.53 | IMAB | I Mab | PairCorr |
0.44 | GNFT | Genfit | PairCorr |
0.43 | FLGC | Flora Growth Corp | PairCorr |
0.34 | LLY | Eli Lilly | PairCorr |
0.32 | PFE | Pfizer Inc Fiscal Year End 4th of February 2025 | PairCorr |
The ability to find closely correlated positions to Aptevo Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aptevo Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aptevo Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aptevo Therapeutics to buy it.
The correlation of Aptevo Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aptevo Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aptevo Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aptevo Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptevo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Aptevo Stock, please use our How to Invest in Aptevo Therapeutics guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aptevo Therapeutics. If investors know Aptevo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aptevo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (415.99) | Quarterly Revenue Growth (1.00) | Return On Assets (0.73) | Return On Equity (2.51) |
The market value of Aptevo Therapeutics is measured differently than its book value, which is the value of Aptevo that is recorded on the company's balance sheet. Investors also form their own opinion of Aptevo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aptevo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aptevo Therapeutics' market value can be influenced by many factors that don't directly affect Aptevo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aptevo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aptevo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aptevo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.